DOI: 10.1055/s-00000069

Seminars in Liver Disease

LinksSchließen

Referenz

Rimassa L, Porta C, Borbath I , et al.
Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT).

J Clin Oncol 2012;
30 (Suppl): Abstract 4006

Bibliographische Angaben herunterladen

Suchen in: